{"id":"NCT05493111","sponsor":"Aerie Pharmaceuticals","briefTitle":"A Long-Term Safety Study Evaluating the Safety and Systemic Exposure of AR-15512","officialTitle":"A Long-Term Safety Study Evaluating the Safety and Systemic Exposure of AR-15512, a Cold Thermoreceptor Modulator, for the Treatment of Dry Eye Disease (COMET-4)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2022-11-01","primaryCompletion":"2024-02-28","completion":"2024-02-28","firstPosted":"2022-08-09","resultsPosted":"2025-08-13","lastUpdate":"2025-08-13"},"enrollment":275,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Dry Eye Disease"],"interventions":[{"type":"DRUG","name":"0.003% AR-15512 ophthalmic solution","otherNames":[]},{"type":"DRUG","name":"AR-15512 vehicle ophthalmic solution","otherNames":[]}],"arms":[{"label":"0.003% AR-15512","type":"EXPERIMENTAL"},{"label":"AR-15512 Vehicle","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the safety of topical ophthalmic 0.003% AR-15512 compared to its vehicle dosed twice daily (BID) in subjects with dry eye disease (DED) for 12 months.","primaryOutcome":{"measure":"Ocular Treatment-Emergent Adverse Events by Preferred Term With Incidence Greater Than 2 Percent","timeFrame":"Day 1 post-treatment, up to Day 365","effectByArm":[{"arm":"0.003% AR-15512","deltaMin":90,"sd":null},{"arm":"AR-15512 Vehicle","deltaMin":7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":10,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":182},"commonTop":["Instillation site pain"]}}